Axsome’s depression drug succeeds in late-stage trial
In a 327-patient trial, the treatment outperformed placebo on a measure of depression after one week and sustained the effect for another five.
Related Articles
ViiV expands licensing deal for its HIV drug in low-income countries
ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, reflecting ongoing pressure to respond to criticism.
Women’s Health, Unstuck
Join Bill Gates and a range of experts for a discussion on flattening barriers to improving women’s health — from research labs to clini…
Federal judge reverses rule that would have removed medical debt from credit reports
A federal judge in Texas removed a Biden-era finalized ruled by the Consumer Financial Protection Bureau that would have removed medical debt from credit reports.
Study finds no evidence aluminum salts in vaccines are tied to higher risk of asthma, other childhood diseases
A new large study from Denmark finds no evidence that aluminum salts used in vaccines are tied to a higher risk of childhood diseases.
HHS efficiency review blamed for delaying patient care at Indian Health Service
Numerous service and staffing cuts at IHS facilities nationally have been caused by a new HHS contract review process, according to IHS workers and emails.
A troubled Sun Pharma plant fails yet another FDA inspection
A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed another inspection last month.
RFK Jr. gives vaccine skeptics plum HHS posts
This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.
Kailera drug shows notable weight loss in China trial
And more biotech news updates, brought to you by The Readout.
Pharmalittle: We’re reading about FDA user fees, rising GLP-1 use by children, and lots more
As FDA kicked off the drug user fee reauthorization process, Commissioner Marty Makary said he’d like to see lower fees paid by industry